CAT

888.24

-3.43%↓

281.82

-3.3%↓

GEV.US

1,047.58

-3.79%↓

RTX

171.14

-2.6%↓

220.49

-3.9%↓

CAT

888.24

-3.43%↓

281.82

-3.3%↓

GEV.US

1,047.58

-3.79%↓

RTX

171.14

-2.6%↓

220.49

-3.9%↓

CAT

888.24

-3.43%↓

281.82

-3.3%↓

GEV.US

1,047.58

-3.79%↓

RTX

171.14

-2.6%↓

220.49

-3.9%↓

CAT

888.24

-3.43%↓

281.82

-3.3%↓

GEV.US

1,047.58

-3.79%↓

RTX

171.14

-2.6%↓

220.49

-3.9%↓

CAT

888.24

-3.43%↓

281.82

-3.3%↓

GEV.US

1,047.58

-3.79%↓

RTX

171.14

-2.6%↓

220.49

-3.9%↓

Начало・Списък с акции・Ocugen Inc

Ocugen Inc

Затворен

1.39 -4.14

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.38

Максимум

1.3900000000000001

Ключови измерители
By Trading Economics
Приходи	-1.5M -19M
Продажби	1.7M 1.5M
EPS	-0.06
Марж на печалбата	-1,250.946
Служители	116
EBITDA	-987K -17M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+732.37% upside

Дивиденти
By Dow Jones
Следващи печалби	31.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-125M 501M
Предишно отваряне	5.53
Предишно затваряне	1.39

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

0.6818 / 0.74 Подкрепа & съпротива

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.05.2026 г., 22:47 ч. UTC

Горещи акции

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15.05.2026 г., 22:16 ч. UTC

Придобивния, сливания и поглъщания

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15.05.2026 г., 22:00 ч. UTC

Значими двигатели на пазара

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15.05.2026 г., 18:09 ч. UTC

Значими двигатели на пазара

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15.05.2026 г., 16:02 ч. UTC

Печалби

Значими двигатели на пазара

Forward Industries Shares Fall on New Debt as Solana Value Drops

15.05.2026 г., 14:55 ч. UTC

Значими двигатели на пазара

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15.05.2026 г., 14:43 ч. UTC

Значими двигатели на пазара

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15.05.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15.05.2026 г., 21:59 ч. UTC

Придобивния, сливания и поглъщания

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15.05.2026 г., 21:50 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15.05.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15.05.2026 г., 21:16 ч. UTC

Пазарно говорене

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

15.05.2026 г., 20:19 ч. UTC

Горещи акции

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15.05.2026 г., 19:41 ч. UTC

Придобивния, сливания и поглъщания

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15.05.2026 г., 19:35 ч. UTC

Пазарно говорене

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15.05.2026 г., 19:33 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15.05.2026 г., 18:35 ч. UTC

Печалби

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15.05.2026 г., 17:28 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15.05.2026 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15.05.2026 г., 16:24 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

15.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

15.05.2026 г., 15:55 ч. UTC

Пазарно говорене

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15.05.2026 г., 15:20 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

15.05.2026 г., 15:20 ч. UTC

Пазарно говорене

Silver Plunges on Inflation Worries -- Market Talk

15.05.2026 г., 15:20 ч. UTC

Печалби

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15.05.2026 г., 14:33 ч. UTC

Пазарно говорене

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

732.37% нагоре

12-месечна прогноза

Среден 11.57 USD 732.37%

Висок 22 USD

Нисък 7 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Ocugen Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.6818 / 0.74Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.